REGN Earnings
Regeneron Pharmaceuticals next reports earnings on July 30, 2026. Track record: 4/4 beats.
Next Earnings In
Thursday, July 30, 2026
Current Price
$664.45
EPS Estimate
Earnings Per Share
$10.41
-19.2% YoY
Trailing EPS
Last 12 months earnings
$41.46
Beat Rate
4/4
100%Forward P/E
Price-to-Earnings ratio
12.1
Margin: 29.6%
Analyst Rating
27 analysts
Analyst Sentiment
Buy27 analystsEarnings History
| Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| 2026-03-31 | $8.90 | $9.47 | +6.4% | Beat |
| 2025-12-31 | $10.75 | $11.44 | +6.4% | Beat |
| 2025-09-30 | $9.64 | $11.83 | +22.7% | Beat |
| 2025-06-30 | $8.44 | $12.89 | +52.7% | Beat |
Growth Estimates
| Period | EPS Est. | Revenue Est. | Growth |
|---|---|---|---|
| Current Qtr(0q) | $10.41 | $3.8B | -19.2% |
| Next Qtr(+1q) | $13.16 | $4.2B | +11.2% |
| Current Year(0y) | $45.99 | $15.9B | +3.8% |
| Next Year(+1y) | $47.72 | $17.6B | +19.1% |
Next Quarter Estimates
EPS Estimate
Earnings Per Share
$10.41
Revenue Estimate
$3.8B
Annual EPS Est.
$45.99
+3.8% YoY
REGN Earnings FAQ
When is REGN's next earnings date?
Regeneron Pharmaceuticals (REGN) is expected to report earnings on July 30, 2026. The consensus EPS estimate is $10.41.
Does REGN usually beat earnings estimates?
Regeneron Pharmaceuticals has beaten Wall Street EPS estimates in 4 of the last 4 quarters (100% beat rate).
What is REGN's trailing EPS?
Regeneron Pharmaceuticals's trailing twelve-month EPS is $41.46. This is calculated from the last four quarters of reported earnings.
What do analysts think about REGN?
27 Wall Street analysts cover Regeneron Pharmaceuticals. The consensus rating is "Buy" with an average price target of $820.72, implying 23.5% upside from the current price.